Spark Therapeutics publicly listed in 2015 and is set to net Children's Hospital of Philadelphia up to $458m following its acquisition by Roche.
Spark Therapeutics, a US-listed gene therapy developer originally spun out from Children’s Hospital of Philadelphia (CHOP), is to be acquired by pharmaceuticals supplier Roche for $114.50 per share, Reuters reported yesterday.
The transaction is anticipated to total $4.3bn when it closes in the second quarter of 2019, generating Spark more than twice its closing price as of February 22.
CHOP’s foundation held a 10.7% stake in Spark as of April 2018, according to Modern Healthcare, and it would…
